“The Buzz” Show: La Jolla Pharmaceutical (NASDAQ: LJPC) Announces Licensing Agreement with PAION AG | Financial Buzz “The Buzz” Show: La Jolla Pharmaceutical (NASDAQ: LJPC) Announces Licensing Agreement with PAION AG

“The Buzz” Show: La Jolla Pharmaceutical (NASDAQ: LJPC) Announces Licensing Agreement with PAION AG

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “La Jolla Pharmaceutical Announces Exclusive Licensing Agreement with PAION AG 

La Jolla Pharmaceutical Company (NASDAQ: LJPC) surged 50% in premarket trading after announcing its exclusive licensing agreement with PAION AG.

La Jolla and certain of its wholly owned subsidiaries have entered into an exclusive licensing agreement with PAION AG and its wholly owned subsidiary for GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland.

La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA™ (angiotensin II) is approved by the U.S. FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA™ (eravacycline) is approved by the U.S. FDA for the treatment of complicated intra-abdominal infections.

For more information, please visit: La Jolla Pharmaceutical Company

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.